Agios Historical Valuation

AGIO Stock  USD 46.02  2.62  5.39%   
Some fundamental drivers such as market cap or Agios Pharm enterprice value can be analyzed from historical perspective to project value of the company into the future. Some investors analyze Agios Pharm valuation indicators such as Working Capital of 0.0 or Enterprise Value of 1.5 B to time the market or to short-sell their positions based on the trend in valuation ratios. It is a perfect tool to project the direction of Agios Pharm's future value.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

About Agios Valuation Data Analysis

Valuation is the financial process of determining what Agios Pharm is worth. Agios Pharm valuation ratios put that insight into the context of a company's share price, where they serve as useful tools for evaluating and utilizing investment potential. Agios Pharm valuation ratios help investors to determine whether Agios Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Agios with respect to the benefits of owning Agios Pharm security.

Agios Pharm Valuation Data Chart

As of the 11th of December 2024, Market Cap is likely to grow to about 1.6 B. Also, Enterprise Value is likely to grow to about 1.5 B

Enterprise Value

Enterprise Value (or EV) is usually referred to as Agios Pharm theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Agios Pharm debt, but would also pocket its cash. Enterprise Value is more accurate representation of Agios Pharm value than its market capitalization because it takes into account all of Agios Pharm existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.

Pair Trading with Agios Pharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.

Moving together with Agios Stock

  0.62DYAI Dyadic InternationalPairCorr
  0.65ESPR Esperion TherapeuticsPairCorr

Moving against Agios Stock

  0.81PFE Pfizer Inc Fiscal Year End 4th of February 2025 PairCorr
  0.77VALN Valneva SE ADRPairCorr
  0.74JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.72LLY Eli LillyPairCorr
  0.68IMAB I MabPairCorr
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
11.66
Revenue Per Share
0.582
Quarterly Revenue Growth
0.212
Return On Assets
(0.18)
Return On Equity
0.5366
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.